Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 14;7(4):732-740.
doi: 10.1016/j.ekir.2022.01.1042. eCollection 2022 Apr.

Thymoglobulin Versus Alemtuzumab Versus Basiliximab Kidney Transplantation From Donors After Circulatory Death

Argiris Asderakis  1 , Tarique K Sabah  1 , William J Watkins  2 , Usman Khalid  1 , Laszlo Szabo  1 , Michael R Stephens  1 , Sian Griffin  1 , Rafael Chavez  1
Affiliations

Thymoglobulin Versus Alemtuzumab Versus Basiliximab Kidney Transplantation From Donors After Circulatory Death

Argiris Asderakis et al. Kidney Int Rep. .

Abstract

Introduction: The Campath, Calcineurin inhibitor (CNI) reduction, and Chronic allograft nephropathy (3C), a study comparing alemtuzumab versus basiliximab induction immunosuppression in kidney transplants, has found lower acute rejection rate with alemtuzumab but same graft survival. The aim of the current study is to evaluate the effect of induction immunosuppression (thymoglobulin, alemtuzumab, basiliximab) on the outcome of kidneys of donors after circulatory death (DCD).

Methods: Data of the 274 DCD patients of the 3C obtained from the sponsor were compounded with the 140 DCD patients who received thymoglobulin in a single center with the same entry criteria as the 3C, giving 414 patients on 3 induction regimes.

Results: There were more male donors (P < 0.05) and human leukocyte antigen and DR mismatched patients in the thymoglobulin group (P < 0.001). Death-censored graft survival at 6 months was 98.6% in the thymoglobulin, 95.5% in the alemtuzumab (P = 0.08), and 95.7% in the basiliximab group (P = 0.09) and at 2 years 97.9% versus 94.8% (P = 0.13, hazard ratio [HR] 2.8, 95% CI 0.7-10.9) versus 94.3% (P = 0.06, HR 3.5, 95% CI 0.9-13.6), respectively.The 2-year overall graft survival was 95% in the thymoglobulin versus 88% in the alemtuzumab (unadjusted P = 0.038, adjusted HR 2.4, 95% CI 0.99-5.9) and 91.4% in the basiliximab group (P = 0.21). The 2-year patient survival was numerically less in the alemtuzumab compared with the thymoglobulin group (91.8% vs. 97.1%, P = 0.052, HR 2.90, 95% CI 0.93-9.2). Acute rejection was 17% in the basiliximab, 4.3% in the thymoglobulin, and 6% in the alemtuzumab group (P < 0.001).

Conclusion: In DCD transplants, thymoglobulin induction may provide advantage over alemtuzumab in patient survival and the same advantage as alemtuzumab over basiliximab in terms of acute rejection. Differing maintenance immunosuppression may contribute to the difference found.

Keywords: alemtuzumab; basiliximab; donation after circulatory death; immunosuppression; kidney transplantation; thymoglobulin.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
Death-censored graft survival. The death-censored graft survival at 2 years was 97.9% in the thymoglobulin compared with 94.8% in the alemtuzumab (P = 0.13, adjusted HR 2.8, 95% CI 0.7–10.9) and 94.3% in the basiliximab group (P = 0.06, adjusted HR 3.5, 95% CI 0.9–13.6). HR, hazard ratio.
Figure 2
Figure 2
Overall graft survival. The 2-year overall graft survival, was 95% in the thymoglobulin compared with 88% in the alemtuzumab group (unadjusted P = 0.038, adjusted HR 2.4, 95% CI 0.99–5.9) and 91% in the basiliximab group (thymo vs. basiliximab P = 0.21). HR, hazard ratio; Thymo, thymoglobulin.
Figure 3
Figure 3
Patient survival. The 2-year patient survival in the thymoglobulin group (97.1%) was better compared with the alemtuzumab group (91.8%, P = 0.05, HR 2.90, 95% CI 0.93–9.2) and similar to the basiliximab group (96.4%, P = 0.72). The difference between basiliximab and alemtuzumab was nonsignificant (P = 0.2). HR, hazard ratio.
See this image and copyright information in PMC

References

    1. NHSBT Transplant activity in the UK—activity report 2018–19. NHSBT. 2019. https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/16537/organ-d... Accessed January 3, 2022. Available at:
    1. NHSBT Organ Donation and Transplantation Activity Report 2019–21. https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/19220/activit... Accessed January 3, 2022. Available at:
    1. Nagaraja P., Roberts G.W., Stephens M., et al. Impact of expanded criteria variables on outcomes of kidney transplantation from donors after cardiac death. Transplantation. 2015;99:226–231. doi: 10.1097/TP.0000000000000304. - DOI - PubMed
    1. Summers D.M., Watson C.J.E., Pettigrew G.J., et al. Kidney donation after circulatory death (DCD): state of the art. Kidney Int. 2015;88:241–249. doi: 10.1038/ki.2015.88. - DOI - PubMed
    1. de Kok M.J.C., Schaapherder A.F.M., Alwayn I.P.J., et al. Improving outcomes for donation after circulatory death kidney transplantation: science of the times. PLoS One. 2020;15 doi: 10.1371/journal.pone.0236662. - DOI - PMC - PubMed

LinkOut - more resources